Stockscreener 앱 받기
22.47
1.75%
-0.40
시간 외 거래:
22.47
전일 마감가:
$22.87
열려 있는:
$22.51
하루 거래량:
376.12K
Relative Volume:
1.43
시가총액:
$1.10B
수익:
-
순이익/손실:
$-82.83M
주가수익비율:
-18.10
EPS:
-1.2413
순현금흐름:
$-72.22M
1주 성능:
-2.94%
1개월 성능:
-11.64%
6개월 성능:
+6.80%
1년 성능:
+84.33%
1일 변동 폭
$21.83
$22.99
1주일 범위
$21.83
$24.42
52주 변동 폭
$10.90
$30.03
Enliven Therapeutics Inc Stock (ELVN) Company Profile
명칭
Enliven Therapeutics Inc
전화
720-647-8519
주소
6200 LOOKOUT ROAD, BOULDER
ELVN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ELVN
Enliven Therapeutics Inc
|
22.47 | 1.10B | 0 | -82.83M | -72.22M | -1.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-13 | 개시 | BTIG Research | Buy |
| 2024-09-09 | 개시 | H.C. Wainwright | Buy |
| 2024-06-11 | 개시 | Robert W. Baird | Outperform |
| 2024-04-09 | 개시 | Mizuho | Buy |
| 2023-03-29 | 개시 | Jefferies | Buy |
Enliven Therapeutics Inc 주식(ELVN)의 최신 뉴스
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Wellington Management Group LLP Purchases 36,267 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - MarketBeat
Lord Abbett & CO. LLC Takes Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - MarketBeat
Enliven Therapeutics (NASDAQ:ELVN) Is In A Good Position To Deliver On Growth Plans - Simply Wall St
When the Price of (ELVN) Talks, People Listen - Stock Traders Daily
Enliven Therapeutics (NASDAQ:ELVN) Now Covered by BTIG Research - MarketBeat
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Acquired by Charles Schwab Investment Management Inc. - MarketBeat
Clear Street sets Enliven Therapeutics stock to buy with $36 target - Investing.com Canada
Enliven Therapeutics (NASDAQ:ELVN) Stock Price Up 6.8%Should You Buy? - MarketBeat
Janus Henderson Group PLC Purchases 313,019 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - MarketBeat
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Sold by RA Capital Management L.P. - MarketBeat
Patient Square Capital LP Takes $2.31 Million Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - MarketBeat
Walleye Capital LLC Takes $2.54 Million Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - MarketBeat
Fmr LLC Boosts Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - MarketBeat
Enliven Therapeutics CFO Benjamin Hohl sells $130,688 in stock By Investing.com - Investing.com Canada
Enliven Therapeutics CFO Benjamin Hohl sells $130,688 in stock - Investing.com
Comparing Enliven Therapeutics (NASDAQ:ELVN) & Terns Pharmaceuticals (NASDAQ:TERN) - Defense World
Enliven Therapeutics (NASDAQ:ELVN) Stock Price Down 3%What's Next? - MarketBeat
Ally Bridge Group NY LLC Takes $6 Million Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - MarketBeat
Acuta Capital Partners LLC Sells 101,330 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - MarketBeat
Enliven Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 - Marketscreener.com
(ELVN) Investment Analysis - Stock Traders Daily
Enliven Therapeutics to Present at the Jefferies London Healthca - GuruFocus.com
Short Interest in Enliven Therapeutics, Inc. (NASDAQ:ELVN) Increases By 6.1% - MarketBeat
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Bought by First Turn Management LLC - MarketBeat
Robert W. Baird Issues Positive Forecast for Enliven Therapeutics (NASDAQ:ELVN) Stock Price - Defense World
Enliven Therapeutics has cash runway into late 2026 - BizWest
Robert W. Baird Forecasts Strong Price Appreciation for Enliven Therapeutics (NASDAQ:ELVN) Stock - MarketBeat
RA Capital Management, L.P. Reduces Stake in Enliven Therapeutics Inc. - GuruFocus.com
COMMODORE CAPITAL LP Expands Stake in Enliven Therapeutics Inc - GuruFocus.com
Citadel Advisors LLC Adjusts Stake in Enliven Therapeutics Inc - GuruFocus.com
Enliven Therapeutics Reports Q3 Results and Clinical Progress - TipRanks
Polar Capital Holdings Plc's Strategic Acquisition in Enliven Th - GuruFocus.com
Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update - PR Newswire
(ELVN) Investment Analysis and Advice - Stock Traders Daily
Enliven Therapeutics to Present at the Jefferies London Healthcare Conference - StockTitan
How to Take Advantage of moves in (ELVN) - Stock Traders Daily
Jones Trading Initiates Coverage of Enliven Therapeutics (ELVN) with Buy Recommendation - MSN
This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Enliven Therapeutics CFO Benjamin Hohl sells shares worth $178,484 By Investing.com - Investing.com South Africa
Enliven Therapeutics CFO Benjamin Hohl sells shares worth $178,484 - Investing.com
Enliven Therapeutics (ELVN) Price Target Increased by 10.75% to 35.02 - MSN
Enliven Therapeutics chief medical officer sells $24,482 in stock - Investing.com India
Enliven Therapeutics CFO sells $24,422 in stock - Investing.com
Enliven Therapeutics chief medical officer sells $24,482 in stock By Investing.com - Investing.com Canada
Enliven Therapeutics COO Anish Patel sells $21,482 in stock - Investing.com
Enliven Therapeutics COO Anish Patel sells $21,482 in stock By Investing.com - Investing.com Australia
Enliven Therapeutics CFO sells $24,422 in stock By Investing.com - Investing.com Canada
Enliven Therapeutics' chief scientific officer sells $25,412 in stock By Investing.com - Investing.com Australia
Enliven Therapeutics CEO Kintz sells $27,722 in stock - Investing.com
Enliven Therapeutics' chief scientific officer sells $25,412 in stock - Investing.com India
Enliven Therapeutics Inc (ELVN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.88%
2.65%
자본화:
|
볼륨(24시간):